Canada tables PMPRB annual report as patented medicine sales rise 10.6%
Canada’s patented medicine market continues to expand, with sales reaching $24.4 billion in 2025 and accounting for nearly half of all medicine sales in the country. The annual review also highlights Canada’s international price ranking and pharmaceutical research spending, underscoring the sector’s weight in the domestic healthcare economy.
Highlights
- Patented medicine sales in Canada rose 10.6% in 2025, representing 48% of all medicine sales according to the PMPRB annual report.
- Canada’s list prices for patented medicines ranked third highest among PMPRB11 countries and seventh among 35 OECD nations in 2025.
- Pharmaceutical rights holders reported $1.73 billion in R&D spending in 2025, yielding a sales-to-R&D ratio of 4.9% as per Patented Medicines Regulations.
Report findings and 2025 market trends
As reported by Canada.ca, citing the Patented Medicine Prices Review Board, Federal Health Minister Marjorie Michel has tabled the board’s 2025 annual report with the clerks of the Senate and the House of Commons. The report examines trends in patented medicine prices and sales, along with updated findings on pharmaceutical research and development and the board’s price review activities in 2025.The board says 1,086 patented medicines for human use were reported to the PMPRB in 2025, including 82 new dosage forms and strengths. Patented medicines represented 48% of all medicine sales in Canada during the year, reflecting the segment’s large share of the national pharmaceutical market.
Price rankings and industry significance
Canada’s list prices ranked third highest among the PMPRB11 countries, behind the UK and Spain, while placing seventh highest among 35 OECD countries. The report also says Canada accounted for 2.1% of worldwide pharmaceutical sales in 2025, making it the world’s eighth largest national market.Rights holders reported $1.73 billion in research and development spending in Canada in 2025, producing an average sales-to-R&D ratio of 4.9% under the definition set out in the Patented Medicines Regulations. The PMPRB says its price reviews are intended to protect Canadians from patent abuse linked to excessive prices while also tracking broader shifts in the pharmaceutical landscape.
As we previously wrote, OSFI’s Competitive Prudential Initiative eased capital rules for smaller Canadian lenders to boost banking competition.